Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Immunomodulators Acting on COVID-19: Actual Knowledge and Perspectives

Version 1 : Received: 5 July 2020 / Approved: 5 July 2020 / Online: 5 July 2020 (17:01:31 CEST)

How to cite: Durán, N.; Fávaro, W.J. Immunomodulators Acting on COVID-19: Actual Knowledge and Perspectives. Preprints 2020, 2020070090 (doi: 10.20944/preprints202007.0090.v1). Durán, N.; Fávaro, W.J. Immunomodulators Acting on COVID-19: Actual Knowledge and Perspectives. Preprints 2020, 2020070090 (doi: 10.20944/preprints202007.0090.v1).

Abstract

Since the outbreak of SARS CoV-2 infection (Covid-19), healthcare professionals worldwide have been trying to find disease management and control alternatives to encourage immunotherapies. Immunotherapy is an efficient therapeutic option used against comparable viral contaminations such as MERS-CoV and SARS-CoV. The aim of the current study is to assess the existing knowledge associated with SARS-CoV-2 immunotherapy. Information available in published articles and their quality highlights the importance of following strict scientific rules for clinical outcomes. Thus, these studies have shown enough data to confirm that immunomodulation is the main topic investigated in research about Covid-19 therapy. Therefore, it is possible saying that immunotherapy is certainly the appropriate option against this virus.

Subject Areas

COVID-19; Immunotherapy; Immunomodulator; Antibody; Plasma; Immunoglobulins

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.